

Supplement to:
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for *CYP2D6*
Genotype and Use of Ondansetron and Tropisetron

Gillian C. Bell¹, Kelly E. Caudle², Michelle Whirl-Carrillo³, Ronald J. Gordon⁴, Keiko Hikino⁵, Cynthia A. Prows⁶, Andrea Gaedigk⁷, Jose A.G. Agundez⁸, Senthilkumar Sadhasivam^{9,10}, Teri E. Klein³, Matthias Schwab^{11, 12, 13}

¹Personalized Medicine Program, Mission Health, Asheville, NC, USA

²Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA

³Department of Genetics, Stanford University, Stanford, CA, USA

⁴University of California, San Diego, Department of Anesthesiology, San Diego, CA, USA

⁵Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago, Chicago, IL, USA

⁶Division of Human Genetics; Division of Patient Services, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA

⁷Division of Clinical Pharmacology, Toxicology & Therapeutic Innovation, Children's Mercy-Kansas City, Kansas City, MO and Department of Pediatrics, University of Missouri-Kansas City, Kansas City, MO, USA

⁸Department of Pharmacology, University of Extremadura, Avda de la Universidad s/n | 10071, Cáceres, Spain

⁹Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, OH, USA

¹⁰Department of Anesthesia, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA

¹¹Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany, and University of Tübingen, Germany

¹²Department of Clinical Pharmacology, University Hospital Tübingen, Tübingen, Germany

¹³Department of Pharmacy and Biochemistry, University of Tübingen, Tübingen, Germany

Corresponding Author:

Matthias Schwab

Professor and Chair of Clinical Pharmacology

Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart and

Department of Clinical Pharmacology, Institute of Experimental and Clinical Pharmacology and Toxicology and

Interfaculty Center for Pharmacogenomics and Drug Research (ICEPHA), University Hospital, Tübingen

Auerbachstrasse 112

70376 Stuttgart

Germany

Phone: ++49 711 8101 3700

Fax: ++49 711 85 92 95

E-mail: matthias.schwab@ikp-stuttgart.de

Alternate email: cpic@pharmgkb.org

TABLE OF CONTENTS

Guideline Updates.....	3
Literature Review.....	3
Gene: <i>CYP2D6</i>	4
Genetic Test Interpretation.....	4
Calculating CYP2D6 Activity Score.....	4
CYP2D6 Structural and Gene Copy Number Variants.....	5
Limitations of the Star (*) Nomenclature and Allele Assignments.....	7
Available Genetic Test Options	8
CYP2D6 Other Considerations	8
Levels of Evidence Linking Genotype to Phenotype	9
Strength of Recommendations.....	10
Resources to Incorporate Pharmacogenetics into an Electronic Health Record with Clinical Decision Support.....	11
Supplemental Table S1. Association between allelic variants ^a and CYP2D6 enzyme activity ...	13
Supplemental Table S2. Evidence linking CYP2D6 to ondansetron and tropisetron phenotype.	15
Supplemental Table S3. Cytochrome P450 enzymes involved in the Metabolism of 5-HT ₃ Receptor Antagonist.....	17
References.....	18

GUIDELINE UPDATES

The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for *CYP2D6* Genotype and Use of Ondansetron and Tropisetron is published in full on the PharmGKB (www.pharmgkb.org) and CPIC websites (cpicpgx.org). Relevant information will be reviewed periodically and updated guidelines published online.

LITERATURE REVIEW

We searched the PubMed® database (1966 to September 2015) for the following keywords: (cytochrome P450 2D6 or CYP2D6) AND (ondansetron, granisetron, tropisetron, palonosetron, ramosetron, 5-HT₃ receptor antagonists). Using these search terms, 43 publications were identified. In addition, studies annotated in PharmGKB (<http://www.pharmgkb.org>) were identified. Study inclusion criteria included publications that included analyses for the association between *CYP2D6* genotypes and metabolism of 5-hydroxytryptamine type 3 antagonists (5-HT₃) or 5-HT₃ antagonist-related adverse drug events or clinical outcomes. Non-English manuscripts were excluded. Following application of these inclusion criteria, 7 publications were reviewed and included in the evidence table (**Supplemental Table S2**).

The *CYP2D6* allele frequency tables (**CYP2D6 frequency table (1)**) are updates of those previously published in CPIC guidelines (2-4). Updates to the *CYP2D6* allele frequency tables were made by searching the PubMed® database (1995 to July 2016). The following criteria were used for *CYP2D6*: (CYP2D6 or 2D6 or cytochrome P4502D6) AND (genotype OR allele OR frequency OR minor allele OR variant OR ethnic OR race OR racial OR ethnicity) with filter limits set to retrieve “full-text” and “English” literature. In addition, reports were also identified from citations by others or review articles. Studies were considered for inclusion in the *CYP2D6* frequency table if: (1) the ethnicity of the population was clearly indicated, (2) either allele frequencies or genotype frequencies were reported, (3) the method by which the genes were genotyped was indicated, (4) the sample population consisted of at least 50 individuals with a few exceptions (e.g., smaller cohorts that were part of larger studies) and (5) the study represented an original publication (no reviews or meta-analyses).

GENE: *CYP2D6*

Genetic Test Interpretation

CYP2D6 genetic variants are typically reported as haplotypes, which are defined by a specific combination of single nucleotide polymorphisms (SNPs) and/or other sequence variants including insertions and deletions that are interrogated during genotyping analysis. *CYP2D6* haplotypes are assigned a star-allele (*) nomenclature to allow for the standardization of genetic polymorphism annotation (5). A complete list of *CYP2D6* star-allele nomenclature along with the genetic variants that define each star-allele is available at <http://www.cypalleles.ki.se/cyp2d6.htm>. Information regarding *CYP2D6* haplotypes (star-alleles) is also available at PharmGKB (***CYP2D6* Allele Definition Table (1)**). Knowing which SNPs or other genetic variants a particular test interrogates is important as the inclusion or exclusion of certain genetic variants in a pharmacogenetic test could affect the reported star-allele result.

Reference laboratories usually report a diplotype, which is the summary of inherited maternal and paternal star-alleles (e.g. *CYP2D6**1/*10, where an individual inherited a *1 allele and a *10 allele). Commonly reported *CYP2D6* star-alleles are categorized into functional groups (e.g., normal function, decreased function, or no function) based on the predicted activity of the encoded enzyme (***CYP2D6* Allele Definition Table (1)**). The predicted phenotype (**Table 1, main manuscript**) is influenced by the expected function of each reported allele in the diplotype. *CYP2D6* phenotype-predicting tools, such as pharmacogenetic translation tables, are being developed by CPIC and can be accessed at www.pharmgkb.org. Hicks *et al.* describes the development of the *CYP2D6* translation table (6).

Calculating CYP2D6 Activity Score. Gaedigk *et al.* developed a scoring system to provide a uniform approach to assigning a predicted *CYP2D6* phenotype (7). *CYP2D6* alleles are assigned an activity value as detailed in **Supplemental Table S1 and S2 (1)**. The activity value of each allele reported in the diplotype is added together to calculate the *CYP2D6* activity score. For example, to calculate the activity score of a *CYP2D6**1/*17 diplotype, the activity value of *1 (activity value = 1) and the activity value of *17 (activity value = 0.5) are totaled to provide the *CYP2D6* activity score of 1.5. Note that a value of 0.5 indicates decreased activity and not that the activity conveyed by an allele is half of that encoded by a normal function allele. For this

guideline, the CYP2D6 activity score is used to assign a predicted phenotype as follows: activity score of 0 = poor metabolizer, activity score of 0.5 = intermediate metabolizer, activity scores ranging from 1.0-2.0 = normal metabolizer, and activity score greater than 2.0 = ultrarapid metabolizer. Therefore, a pharmacogenetic test result of *CYP2D6**1/*17 would result in a CYP2D6 activity score of 1.5 and a predicted phenotype of normal metabolizer.

There is a lack of consensus in regards to whether patients with a CYP2D6 activity score of 1.0 should be assigned a normal or intermediate phenotype (3). Pharmacokinetic data suggest that patients with an activity score of 1.0 have a higher CYP2D6 metabolic capacity compared to patients with an activity score of 0.5, but less CYP2D6 enzyme activity compared to patients with an activity score of 2.0 (7). Herein, we classified patients with a CYP2D6 activity score of 1.0 as normal metabolizers, which is consistent with the CPIC guidelines for codeine, the tricyclic antidepressants and SSRIs (4, 7, 8).

CYP2D6 Structural and Gene Copy Number Variants. Because *CYP2D6* is subject to copy number variation (gene duplications, multiplications, or deletions), clinical laboratories may report gene copy number if directly tested. Most patients will have a normal copy number of 2, with one gene copy inherited maternally and one gene copy inherited paternally. When two *CYP2D6* gene copies are present, the diplotype may be reported as follows: *CYP2D6**1/*1 or *CYP2D6* (*1/*1)2N, where “2” represents the gene copy number. A copy number of “1” indicates the presence of a *CYP2D6* gene deletion (the patient possesses only one gene copy), and a copy number of “0” indicates both *CYP2D6* genes are deleted. *CYP2D6* gene deletions are indicated by the *CYP2D6**5 allele. A gene deletion that is present on one chromosome may be reported as follows: *CYP2D6**2/*5 or *CYP2D6* (*2/*2)1N, where “1” represents gene copy number and the *CYP2D6**5 allele is inferred. Typically, clinical laboratories will report a homozygous gene deletion as *CYP2D6**5/*5 or *CYP2D6* (*5/*5)0N.

A copy number greater than two indicates the presence of a *CYP2D6* gene duplication or multiplication. When a *CYP2D6* gene duplication is present, the diplotype may be reported as *CYP2D6* (*1/*2)3N, where “3” represents gene copy number. A clinical laboratory may not report an exact copy number, but rather indicate that additional copies of the *CYP2D6* gene are present (e.g., *CYP2D6**1/*2 duplication or *CYP2D6* (*1/*2)xN). In instances where a

duplication/multiplication is present and the exact copy number is not reported, most patients will likely have a *CYP2D6* gene copy number of 3. However, individuals carrying as many as 13 *CYP2D6* gene copies have been reported (9). Clinical laboratories typically do not determine which allele is duplicated, therefore when calculating CYP2D6 activity score the duplication must be considered for each allele reported in the diplotype (10). For example, a genotype result of *CYP2D6* (*1/*4)3N indicates a patient has three copies of the *CYP2D6* gene, with either two copies of the *CYP2D6**1 allele and one copy of the *CYP2D6**4 allele, or one copy of the *CYP2D6**1 allele and two copies of the *CYP2D6**4 allele. If the *CYP2D6**1 allele carries the duplication, the CYP2D6 activity score of this diplotype will be 2, whereas if the *CYP2D6**4 allele carries the duplication, the activity score will be 1. Likewise, if the number of gene copies is not determined and it remains unknown which allele carries the duplication/multiplication, a *CYP2D6* (*4/*9)xN genotype, for example, can be consistent with an IM (intermediate metabolizer) phenotype (*CYP2D6**4xN/*9; activity score of 0.5) or an NM (normal metabolizer) phenotype (*CYP2D6**4/*9xN assuming that xN does not exceed four copies in which case the activity score is 1 for xN=2, 1.5 for xN=3 and 2 for xN=4). As these examples illustrate, phenotype prediction will be considerably more accurate if testing determines which allele carries the duplication/multiplication and determines the number of gene copies present. Studies have been published describing the translation of *CYP2D6* genotypes into predicted phenotypes when gene duplications or multiplications are present (2, 7, 10-12).

Note that a duplication may not be detected by copy number assays when paired with the *CYP2D6**5 allele (gene deletion). A *CYP2D6**2x2/*5 diplotype, for example, has a gene duplication on one allele and a gene deletion on the other for a total number of two gene copies. This diplotype may be reported as *CYP2D6**2/*2.

Other structural variants include gene copies that consist of *CYP2D6* and *CYP2D7*-derived sequences (13, 14). The no function *CYP2D7-2D6* hybrid genes, collectively assigned as *CYP2D6**13 (15), may not be detected by a particular genotype test or gene copy number testing. In such cases the test may detect only the allele present on the second chromosome and report the diplotype as homozygous for that allele. For example, a test that does not detect *CYP2D6**13 will report a *CYP2D6**1/*13 diplotype as *CYP2D6**1/*1. Hybrid genes can also occur in duplication configurations and cause positive gene duplication test results that may lead to an

overestimation of activity and false-positive prediction of ultrarapid metabolism (14, 16). For example, a *CYP2D6**1/*13+*2 diplotype (activity score = 2 predicting normal metabolism) may be assigned as *CYP2D6**1/*2xN (activity score =3 predicting ultrarapid metabolism).

Limitations of the Star (*) Nomenclature and Allele Assignments. The star (*) nomenclature has defined multiple subvariants for an allele (e.g. *CYP2D6**2 and *4), but generally, these are not distinguished by current testing. This is of no consequence for *CYP2D6**4, because all *4 subvariants share 1846G>A causing aberrant splicing and absence of functional protein. For *CYP2D6**2, however, it is uncertain whether any of the sequence variations defining the suballeles convey a functional consequence. Also, there is no, or little, information regarding their frequencies because test laboratories do not discriminate the suballeles. In addition, there are numerous known variants and subvariants of uncertain function that have not been designated by the nomenclature committee.

It also needs to be realized that the accuracy of a genotype test depends on the number of sequence variations/allelic variants tested. If no variation is found, a *CYP2D6**1 will be the ‘default’ assignment. Depending on which sequence variations are found, the default assignment will be *CYP2D6**2 (or other). For example, if 2850C>T is present, but 1023C>T is not, the default assignment is *CYP2D6**2. Also see ‘CYP2D6 Other Considerations’ below.

Recent findings indicate that a SNP in a distal enhancer region impacts allele activity on the transcriptional level (17, 18). It is not fully understood on which allelic variants this enhancer SNP is located. Emerging knowledge, however, suggests that a portion of *CYP2D6**2 alleles carrying the enhancer SNP convey normal function while others lacking the enhancer SNP have decreased function; the effect of the enhancer SNP in other haplotypes remains unknown. Presence or absence of the enhancer SNP likely also impacts the activity encoded by *CYP2D6**2xN (duplications and multiplications). This SNP is, however, not included in current test panels. The activity score will be updated, if warranted, as new information becomes available.

Available Genetic Test Options

Commercially available genetic testing options change over time. Additional information about pharmacogenetic testing can be found at the Genetic Testing Registry (<http://www.ncbi.nlm.nih.gov/gtr/>). The American College of Medical Genetics and Genomics (ACMG) established guidelines for laboratory testing of *CYP2D6* in relation to tamoxifen therapy (19).

Clinical laboratories may analyze for different SNPs or other genetic variants, which are dependent on the genotyping platforms used and may affect the reported diplotype leading to discrepant results between methodologies. Additionally, laboratories may differ in how *CYP2D6* copy number variants are reported, which can potentially affect phenotype prediction. Therefore, it is important to not only know the alleles interrogated by each laboratory, but also which sequence variants (e.g., SNPs, insertions, or deletions) are tested and how copy number variants are reported. Clinical laboratories commonly give an interpretation of the genotype result and provide a predicted phenotype. Phenotype assignment for this guideline is defined in the main manuscript and supplementary data, but may differ from some clinical laboratory interpretations. Any *CYP2D6* genotyping results used to guide patient pharmacotherapy and/or deposited into patient medical records should be derived from validated genotyping platforms in clinical laboratories that implement the appropriate regulatory standards and best practices (e.g., CAP, CLIA).

CYP2D6 Other Considerations

There are several factors that cause potential uncertainty in *CYP2D6* genotyping results and phenotype predictions as follows: **1)** Because it is currently impractical to test for every variation in the *CYP2D6* gene, genotyping tests may not detect rare variants resulting in patients being assigned a default genotype. It also needs to be stressed that genotyping tests are not designed to detect unknown/*de novo* sequence variations. Depending on the sequence variations (or alleles present) in a given patient, the default genotype may be *CYP2D6**1/*1 (or wild-type) or another diplotype. If the rare or *de novo* variant adversely affects *CYP2D6* enzyme function, then the patient's actual phenotype may differ from the predicted phenotype. **2)** Sub-alleles of *CYP2D6**4 have been identified that harbor additional SNPs with limited or no added functional consequence (e.g., *CYP2D6**4A, *4B, *4C, and *4D). Therefore, only analyzing for the defining

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron—Supplemental v1.0

*CYP2D6**4 SNPs (100C>T and 1846G>A) is usually sufficient to determine a *CYP2D6* phenotype. **3)** There are multiple gene units involved in duplication and other major rearrangements. Additionally, the pseudogenes *CYP2D7* and *CYP2D8* may be misinterpreted as functional duplications (20). If the specific gene units involved in the duplication or other rearrangements are not specifically tested for, the phenotype prediction may be inaccurate and *CYP2D6* activity over-estimated. **4)** Some SNPs exist on multiple alleles. For example, *CYP2D6**69 carries the defining SNPs for *CYP2D6**41 (2850C>T, 2988G>A, and 4180G>C) and the defining SNPs for *CYP2D6**10 (100C>T and 4180G>C) in addition to multiple other SNPs. If a patient carries these genetic variants (in the absence of 1846G>A), a *CYP2D6**10/*41 diplotype is typically assigned, because this is the most likely result based on allele frequencies. However, a *CYP2D6**1/*69 genotype cannot be excluded with certainty. Testing for additional SNPs (e.g., 1062A>G, 3384A>C, and 3584G>A) could exclude *CYP2D6**1/*69 with certainty. Therefore, to unequivocally determine the presence of certain alleles, testing for multiple SNPs may be required. **5)** Allele frequencies may vary considerably among individuals of different ethnic backgrounds. For instance, *CYP2D6**10 is common in Asian populations while *CYP2D6**17 is common in people of Sub-Saharan African ancestry. These alleles, however, have a considerably lower prevalence in other ethnic groups such as Caucasians of European ancestry. As another example, *CYP2D6**14 is present in Asian populations and therefore its defining SNP (1758G>A) has been incorporated into Asian genotyping panels (21). Thus, the alleles that should be tested for a given population may vary considerably. **6)** Certain alleles carry genes in tandem arrangements. One such example is *CYP2D6**36+*10 (one copy of the non-functional *CYP2D6**36 and one copy of the decreased function *CYP2D6**10). This tandem can be found in Asians and is typically reported as a default assignment of *CYP2D6**10.

LEVELS OF EVIDENCE LINKING GENOTYPE TO PHENOTYPE

The evidence summarized in **Supplemental Tables S2** is graded (22) on a scale of high, moderate, and weak, based upon the level of evidence:

High: Evidence includes consistent results from well-designed, well-conducted studies.

Moderate: Evidence is sufficient to determine effects, but the strength of the evidence is limited by the number, quality, or consistency of the individual studies, generalizability to routine practice, or indirect nature of the evidence.

Weak: Evidence is insufficient to assess the effects on health outcomes because of limited number or power of studies, important flaws in their design or conduct, gaps in the chain of evidence, or lack of information.

Every effort was made to present evidence from high-quality studies, which provided the framework for the strength of therapeutic recommendations (**Table 2**, main manuscript).

STRENGTH OF RECOMMENDATIONS

CPIC's therapeutic recommendations are based on weighing the evidence from a combination of preclinical functional and clinical data, as well as on some existing disease-specific consensus guidelines. Some of the factors that are taken into account in evaluating the evidence supporting therapeutic recommendations include: in vivo pharmacokinetic and pharmacodynamic data, in vitro enzyme activity of tissues expressing wild-type or variant-containing CYP2D6, in vitro CYP2D6 enzyme activity from tissues isolated from individuals of known *CYP2D6* genotypes, and in vivo pre-clinical and clinical pharmacokinetic and pharmacodynamic studies.

Overall, the therapeutic recommendations are simplified to allow rapid interpretation by clinicians. CPIC uses a slight modification of a transparent and simple system for just three categories for recommendations adopted from the rating scale for evidence-based recommendations on the use of antiretroviral agents (23):

Strong recommendation for the statement: “The evidence is high quality and the desirable effects clearly outweigh the undesirable effects.”

Moderate recommendation for the statement: “There is a close or uncertain balance” as to whether the evidence is high quality and the desirable clearly outweigh the undesirable effects.

Optional recommendation for the statement: The desirable effects are closely balanced with undesirable effects, or the evidence is weak or based on extrapolations. There is room for differences in opinion as to the need for the recommended course of action.

No recommendation: There is insufficient evidence, confidence, or agreement to provide a recommendation to guide clinical practice at this time

RESOURCES TO INCORPORATE PHARMACOGENETICS INTO AN ELECTRONIC HEALTH RECORD WITH CLINICAL DECISION SUPPORT

Clinical decision support (CDS) tools integrated within electronic health records (EHRs) can help guide clinical pharmacogenetics at the point of care (24-28). See <https://cpicpgx.org/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype> for resources to support the adoption of CPIC guidelines within an EHR (29). Based on the capabilities of various EHRs and local preferences, we recognize that approaches may vary across organizations. Our intent is to synthesize foundational knowledge that provides a common starting point for incorporating *CYP2D6* genotype results in an EHR to guide ondansetron and tropisetron dosing.

Effectively incorporating pharmacogenetic information into an EHR to optimize drug therapy should have some key attributes. Pharmacogenetic results, an interpreted phenotype, and a concise interpretation or summary of the result must be documented in the EHR (6). To incorporate a phenotype in the EHR in a standardized manner, genotype test results provided by the laboratory must be consistently translated into an interpreted phenotype (**Table 1, main manuscript**). Because clinicians must be able to easily find the information, the interpreted phenotype may be documented as a problem list entry or in a patient summary section; these phenotypes are best stored in the EHR at the “person level” rather than at the date-centric “encounter level”. Additionally, results should be entered as standardized and discrete terms to facilitate using them to provide point-of-care CDS (30, 31).

Because pharmacogenetic results have lifetime implications and clinical significance, results should be placed into a section of the EHR that is accessible independent of the test result date to allow clinicians to quickly find the result at any time after it is initially placed in the EHR. To facilitate this process, CPIC is providing gene-specific information figures and tables that include full diplotype to phenotype tables, diagram(s) that illustrate how *CYP2D6* pharmacogenetic test results could be entered into an EHR, example EHR consultation/genetic test interpretation language and widely used nomenclature systems (see <https://www.pharmgkb.org/page/cyp2d6RefMaterials>)(1). Point-of-care CDS should be designed to effectively notify clinicians of prescribing implications at any time after the test result is

entered into the EHR. CPIC is also providing gene-drug specific tables that provide guidance to achieve these objectives with diagrams that illustrate how point-of-care CDS should be entered into the EHR, example pre- and post-test alert language, and widely used nomenclature systems for relevant drugs (see <https://cpicpgx.org/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype>).

SUPPLEMENTAL TABLE S1. ASSOCIATION BETWEEN ALLELIC VARIANTS^a AND CYP2D6 ENZYME ACTIVITY

Functional Status (2, 7)	Activity Value ^{c,d}	Alleles
Increased function	>1	*1xN, *2xN, *35xN, *45 ^g xN
Normal or Increased function	1 or >1 ^h	*9xN, *10xN, *17xN, *29xN, *41xN
Normal function ^b	1	*1 ^e , *2, *27, *33, *34 ^f , *35, *39 ^f , *45 ^g , *46 ^g , *48, *53
Decreased function	0.5	*9, *10, *14B, *17, *29, *41, *49, *50, *54, *55, *59, *72
No function	0	*3, *3xN, *4, *4xN, *5, *6, *6xN, *7, *8, *11, *12, *13, *14A, *15, *18, *19, *20, *21, *31, *36, *36xN, *38, *40, *42, *44, *47, *51, *56, *57, *62, *68, *69, *92, *100, *101
Unknown	N/A	*22, *23, *24, *25, *26, *28, *30, *32, *37, *43, *43xN, *52, *58, *60, *61, *63, *64, *65, *70, *71, *73, *74, *75, *81, *82, *83, *84, *85, *86, *87, *88, *89, *90, *91, *93, *94, *95, *96, *97, *98, *102, *103, *104, *105, *107, *108, *109

^aSee <http://www.cypalleles.ki.se/cyp2d6.htm> or **CYP2D6 Allele Definition Table (1)** for updates on CYP2D6 allelic variants and nomenclature.

^bAn important caveat for all genotyping tests is that the decision to assign an allele a wild-type status is based upon a genotyping test that interrogates only the most common and already-proven sites of functional variation. It is always possible that a new, previously undiscovered (and therefore un-interrogated) site of variation is defaulted to a functional allele assignment (wild-type). There is a rare possibility that such variation confers decreased or no function in an individual and that the person's CYP2D6 function is not accurately predicted.

^cFor some allelic variants there is no or sparse information regarding their activity; therefore no value can be assigned and no CYP2D6 activity score can be calculated. In such cases, the activity score may be estimated based on the second/known allele. A recent in vitro investigation using tamoxifen as substrate provides preliminary information for alleles listed here as unknown (32).

^dFor certain *CYP2D6* alleles *in vivo* data are lacking to unambiguously assign an activity value. For instance, the *CYP2D6**10 and *17 activity values may be substrate dependent, and for particular drugs the activity value could be closer to 1 (normal function) or 0 (no function). It should be noted that the CYP2D6 activity score is an ordinal scale. An allele with an activity score of 0.5 does not necessarily have half the metabolic activity of an allele with an activity score of 1. Rather the score of 0.5 indicates the allele has decreased metabolic activity when compared to the *CYP2D6**1 reference allele.

^e*CYP2D6**1 serves as reference and is defined as wild-type.

^fFunction of *CYP2D6**34 and *39 is extrapolated from *2. Both star alleles have SNP(s) that are part of the *2 haplotype.

^gLimited data are available to determine the predicted activity value of *CYP2D6**45 and *46. Although an activity value of 1 (normal function) is assigned to *CYP2D6**45 and *46 in this guideline, others may assign an activity value of 0.5 (decreased function).

^hActivity value is dependent on the number of duplications/multiplications present.

SUPPLEMENTAL TABLE S2. EVIDENCE LINKING CYP2D6 TO ONDANSETRON AND TROPISETRON PHENOTYPE

Type of experimental model (in vitro, in vivo, preclinical or clinical)	Major findings	References	Level of evidence ^a
Clinical	<i>CYP2D6</i> gene duplication is associated with decreased ondansetron AUC for S-ondansetron enantiomer only (no influence on racemic mixture).	Stamer, et al. (2011)(33)	Moderate
Clinical	<i>CYP2D6</i> genotype/phenotype has no effect on ondansetron concentrations (racemic mixture).	Rauers, et al. (2010)(34) Ashforth, et al. (1994)(35)	Weak
Clinical	<i>CYP2D6</i> gene duplication is associated with decreased response to ondansetron (i.e. vomiting) when used for prevention of postoperative nausea and vomiting.	Candiotti, et al. (2005)(36)	Moderate
Clinical	<i>CYP2D6</i> gene duplication is associated with decreased response to ondansetron (i.e. vomiting) when used for prevention or treatment of chemotherapy-induced nausea and vomiting.	Kaiser, et al. (2002)(37)	Weak
Clinical	<i>CYP2D6</i> intermediate metabolizer genotype is not associated with response to ondansetron as compared to normal metabolizers. Note: Based on the CPIC/Gaedigk activity score some diplotypes classified as intermediate metabolizers would be classified as normal metabolizers in CPIC guidelines (e.g., <i>CYP2D6</i> *2/*4).	Perwitasari, et al. (2011)(38)	Weak
Clinical	<i>CYP2D6</i> ultrarapid metabolizer genotype is associated with decreased tropisetron AUC as compared to <i>CYP2D6</i> normal metabolizers.	Kim, et al. (2003)(39)	Weak

Clinical	CYP2D6 intermediate metabolizer ^b genotype is associated with increased tropisetron AUC as compared to the CYP2D6 normal metabolizer genotype.	Kim, et al. (2003)(39)	Weak
Clinical	CYP2D6 poor metabolizer genotype had higher serum concentrations of tropisetron than all other patients.	Kaiser, et al. (2002)(37)	Moderate
Clinical	<i>CYP2D6</i> gene duplication is associated with decreased response to tropisetron (i.e. vomiting) when used for prevention or treatment of chemotherapy-induced nausea and vomiting.	Kaiser, et al. (2002)(37)	Moderate

^aHigh: Evidence includes consistent results from well-designed, well-conducted studies.

Moderate: Evidence is sufficient to determine effects, but the strength of the evidence is limited by the number, quality, or consistency of the individual studies; generalizability to routine practice; or indirect nature of the evidence.

Weak: Evidence is insufficient to assess the effects on health outcomes because of limited number or power of studies, important flaws in their design or conduct, gaps in the chain of evidence, or lack of information

^bManuscript describes these individuals as poor metabolizers. Per CPIC/Gaedigk activity scores, all these patients are intermediate metabolizers.

SUPPLEMENTAL TABLE S3. CYTOCHROME P450 ENZYMES INVOLVED IN THE METABOLISM OF 5-HT₃ RECEPTOR ANTAGONIST

	CYP1A1	CYP1A2	CYP2D6	CYP3A4/5	Reference
Dolansetron	-	-	+	+	Sanwald, <i>et al.</i> (1996) (40)
Ganisetron	-	-	-	+	Bloomer, <i>et al.</i> (1994) (41)
Ondansetron	+	+	+	+	Sanwald, <i>et al.</i> (1996) (40) Dixon, <i>et al.</i> (1995) (42) Fischer, <i>et al.</i> (1994) (43)
Palonosetron	-	+	+	+	MGI Pharma (44)
Ramosetron	+	+	+	-	Kadokura, <i>et al.</i> (45)
Tropisetron	-	-	+	+	Sanwald, <i>et al.</i> (1996) (40) Fischer, <i>et al.</i> (1994) (43) Firkusny, <i>et al.</i> (1995) (46)

REFERENCES

1. Gene Reference Materials for CYP2D6: PharmGKB; [Available from: <https://www.pharmgkb.org/page/cyp2d6RefMaterials>].
2. Crews KR, Gaedigk A, Dunnenberger HM, Klein TE, Shen DD, Callaghan JT, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. *Clinical pharmacology and therapeutics*. 2012;91(2):321-6.
3. Crews KR, Gaedigk A, Dunnenberger HM, Leeder JS, Klein TE, Caudle KE, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. *Clin Pharmacol Ther*. 2014;95(4):376-82.
4. Hicks JK, Bishop JR, Sangkuhl K, Muller DJ, Ji Y, Leckband SG, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. *Clinical pharmacology and therapeutics*. 2015;98(2):127-34.
5. Robarge JD, Li L, Desta Z, Nguyen A, Flockhart DA. The star-allele nomenclature: retooling for translational genomics. *Clinical pharmacology and therapeutics*. 2007;82(3):244-8.
6. Hicks JK, Crews KR, Hoffman JM, Kornegay NM, Wilkinson MR, Lorier R, et al. A clinician-driven automated system for integration of pharmacogenetic interpretations into an electronic medical record. *Clinical pharmacology and therapeutics*. 2012;92(5):563-6.
7. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. *Clin Pharmacol Ther*. 2008;83(2):234-42.
8. Hicks JK, Swen JJ, Gaedigk A. Challenges in CYP2D6 phenotype assignment from genotype data: a critical assessment and call for standardization. *Current drug metabolism*. 2014;15(2):218-32.
9. Dahl ML, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjoqvist F. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. *The Journal of pharmacology and experimental therapeutics*. 1995;274(1):516-20.
10. Ramamoorthy A, Skaar TC. Gene copy number variations: it is important to determine which allele is affected. *Pharmacogenomics*. 2011;12(3):299-301.
11. Hicks JK, Crews KR, Hoffman JM, Kornegay NM, Wilkinson MR, Lorier R, et al. A Clinician-Driven Automated System for Integration of Pharmacogenetic Interpretations Into an Electronic Medical Record. *Clinical pharmacology and therapeutics*. 2012.
12. Gaedigk A, Sangkuhl K, Whirl-Carrillo M, Klein T, Leeder JS. Prediction of CYP2D6 phenotype from genotype across world populations. *Genet Med*. 2016.
13. Gaedigk A, Jaime LK, Bertino JS, Jr., Berard A, Pratt VM, Bradfordand LD, et al. Identification of Novel CYP2D7-2D6 Hybrids: Non-Functional and Functional Variants. *Front Pharmacol*. 2010;1:121.
14. Gaedigk A. Complexities of CYP2D6 gene analysis and interpretation. *Int Rev Psychiatry*. 2013;25(5):534-53.
15. Sim SC, Daly AK, Gaedigk A. CYP2D6 update: revised nomenclature for CYP2D7/2D6 hybrid genes. *Pharmacogenet Genomics*. 2012;22(9):692-4.
16. Gaedigk A, Fuhr U, Johnson C, Berard LA, Bradford D, Leeder JS. CYP2D7-2D6 hybrid tandems: identification of novel CYP2D6 duplication arrangements and implications for phenotype prediction. *Pharmacogenomics*. 2010;11(1):43-53.

17. Wang D, Papp AC, Sun X. Functional characterization of CYP2D6 enhancer polymorphisms. *Human molecular genetics*. 2014.
18. Wang D, Poi MJ, Sun X, Gaedigk A, Leeder JS, Sadee W. Common CYP2D6 polymorphisms affecting alternative splicing and transcription: long-range haplotypes with two regulatory variants modulate CYP2D6 activity. *Human molecular genetics*. 2014;23(1):268-78.
19. Lyon E, Gastier Foster J, Palomaki GE, Pratt VM, Reynolds K, Sabato MF, et al. Laboratory testing of CYP2D6 alleles in relation to tamoxifen therapy. *Genet Med*. 2012.
20. Meijerman I, Sanderson LM, Smits PH, Beijnen JH, Schellens JH. Pharmacogenetic screening of the gene deletion and duplications of CYP2D6. *Drug metabolism reviews*. 2007;39(1):45-60.
21. Kim EY, Lee SS, Jung HJ, Jung HE, Yeo CW, Shon JH, et al. Robust CYP2D6 genotype assay including copy number variation using multiplex single-base extension for Asian populations. *Clinica chimica acta; international journal of clinical chemistry*. 2010;411(23-24):2043-8.
22. Valdes R, Payne DA, Linder MW. Laboratory analysis and application of pharmacogenetics to clinical practice. *The National Academy of Clinical Biochemistry (NACB) - Laboratory Medicine Practice Guidelines*. Washington, DC2010.
23. Adolescents PoAGfAa. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 2011. p. 1-166.
24. Shuldiner AR, Relling MV, Peterson JF, Hicks JK, Freimuth RR, Sadee W, et al. The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. *Clinical pharmacology and therapeutics*. 2013;94(2):207-10.
25. Wilke RA, Xu H, Denny JC, Roden DM, Krauss RM, McCarty CA, et al. The emerging role of electronic medical records in pharmacogenomics. *Clinical pharmacology and therapeutics*. 2011;89(3):379-86.
26. Peterson JF, Bowton E, Field JR, Beller M, Mitchell J, Schildcrout J, et al. Electronic health record design and implementation for pharmacogenomics: a local perspective. *Genet Med*. 2013;15(10):833-41.
27. Gottesman O, Kuivaniemi H, Tromp G, Faucett WA, Li R, Manolio TA, et al. The Electronic Medical Records and Genomics (eMERGE) Network: past, present, and future. *Genet Med*. 2013;15(10):761-71.
28. Kullo IJ, Jarvik GP, Manolio TA, Williams MS, Roden DM. Leveraging the electronic health record to implement genomic medicine. *Genet Med*. 2013;15(4):270-1.
29. Hoffman JM, Dunnenberger HM, Kevin Hicks J, Caudle KE, Whirl Carrillo M, Freimuth RR, et al. Developing knowledge resources to support precision medicine: principles from the Clinical Pharmacogenetics Implementation Consortium (CPIC). *J Am Med Inform Assoc*. 2016;23(4):796-801.
30. Bell GC, Crews KR, Wilkinson MR, Haidar CE, Hicks JK, Baker DK, et al. Development and use of active clinical decision support for preemptive pharmacogenomics. *J Am Med Inform Assoc*. 2013.
31. Pulley JM, Denny JC, Peterson JF, Bernard GR, Vnencak-Jones CL, Ramirez AH, et al. Operational Implementation of Prospective Genotyping for Personalized Medicine: The Design of the Vanderbilt PREDICT Project. *Clinical pharmacology and therapeutics*. 2012;92(1):87-95.

32. Muroi Y, Saito T, Takahashi M, Sakuyama K, Niinuma Y, Ito M, et al. Functional Characterization of Wild-type and 49 CYP2D6 Allelic Variants for N-Desmethyldoxylifen 4-Hydroxylation Activity. *Drug metabolism and pharmacokinetics*. 2014;29(5):360-6.
33. Stamer UM, Lee EH, Rauers NI, Zhang L, Kleine-Brueggeney M, Fimmers R, et al. CYP2D6- and CYP3A-dependent enantioselective plasma concentrations of ondansetron in postanesthesia care. *Anesth Analg*. 2011;113(1):48-54.
34. Rauers NI, Stuber F, Lee EH, Musshoff F, Fimmers R, Barann M, et al. Antagonistic effects of ondansetron and tramadol? A randomized placebo and active drug controlled study. *J Pain*. 2010;11(12):1274-81.
35. Ashforth EI, Palmer JL, Bye A, Bedding A. The pharmacokinetics of ondansetron after intravenous injection in healthy volunteers phenotyped as poor or extensive metabolisers of debrisoquine. *Br J Clin Pharmacol*. 1994;37(4):389-91.
36. Candiotti KA, Birnbach DJ, Lubarsky DA, Nhuch F, Kamat A, Koch WH, et al. The impact of pharmacogenomics on postoperative nausea and vomiting: do CYP2D6 allele copy number and polymorphisms affect the success or failure of ondansetron prophylaxis? *Anesthesiology*. 2005;102(3):543-9.
37. Kaiser R, Sezer O, Papies A, Bauer S, Schelenz C, Tremblay PB, et al. Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. *J Clin Oncol*. 2002;20(12):2805-11.
38. Perwitasari DA, Wessels JA, van der Straaten RJ, Baak-Pablo RF, Mustofa M, Hakimi M, et al. Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy. *Jpn J Clin Oncol*. 2011;41(10):1168-76.
39. Kim MK, Cho JY, Lim HS, Hong KS, Chung JY, Bae KS, et al. Effect of the CYP2D6 genotype on the pharmacokinetics of tropisetron in healthy Korean subjects. *Eur J Clin Pharmacol*. 2003;59(2):111-6.
40. Sanwald P, David M, Dow J. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT3 antagonists. *Drug Metab Dispos*. 1996;24(5):602-9.
41. Bloomer JC, Baldwin SJ, Smith GJ, Ayrtton AD, Clarke SE, Chenery RJ. Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron. *Br J Clin Pharmacol*. 1994;38(6):557-66.
42. Dixon CM, Colthup PV, Serabjit-Singh CJ, Kerr BM, Boehlert CC, Park GR, et al. Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. *Drug Metab Dispos*. 1995;23(11):1225-30.
43. Fischer V, Vickers AE, Heitz F, Mahadevan S, Baldeck JP, Minery P, et al. The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron. *Drug Metab Dispos*. 1994;22(2):269-74.
44. MGI Pharma: Aloxi (palonosetron HCl injection) prescribing information. MGI Pharma2004.
45. Kadokura T, den Adel M, Krauwinkel WJ, Takeshige T, Nishida A. The effect of paroxetine on the pharmacokinetics, safety, and tolerability of ramosetron in healthy subjects. *Eur J Clin Pharmacol*. 2008;64(6):605-9.
46. Firkusny L, Kroemer HK, Eichelbaum M. In vitro characterization of cytochrome P450 catalysed metabolism of the antiemetic tropisetron. *Biochem Pharmacol*. 1995;49(12):1777-84.